Fatima Ashraf Mughal

Inflammatory Bowel Disease (IBD), which includes Crohn’s Disease (CD) and Ulcerative Colitis (UC), is a long-term condition caused by abnormal immune responses that lead to ongoing inflammation in the gut. Its roots are complex, involving a mix of genetics, environmental triggers, gut bacteria, and immune system issues. In recent years, the way we treat IBD has changed dramatically. We’ve moved beyond just managing symptoms with anti-inflammatory and immunosuppressive drugs. Now, we use biologic therapies—advanced treatments made from living cells that target specific parts of the immune system responsible for inflammation. A major breakthrough came with TNF-α inhibitors like infliximab and adalimumab. These drugs help many patients achieve remission, heal their intestinal lining, and feel significantly better overall. For those who don’t respond to these first-line options, newer treatments like vedolizumab (which targets integrins) and ustekinumab (which blocks interleukins IL-12 and IL-23) offer promising alternatives. Still, not everything is perfect. Some patients don’t respond to treatment right away, and others may stop responding over time, often due to their immune systems producing antibodies against the medication. When that happens, doctors might adjust the dose, switch to a different drug, or combine treatments to improve results. While many biologics affect the whole immune system, gut-specific drugs like vedolizumab offer a safer option for long-term use. Cost is another challenge, but biosimilars affordable versions of biologic drugs are making these treatments more accessible, especially in countries with limited healthcare resources. Even so, outcomes can differ from person to person based on how severe their disease is and how well they stick to their treatment plan. Looking ahead, the future of IBD treatment is all about personalized medicine. Scientists are working on finding biomarkers that can help predict which treatment will work best for each individual. New drugs, including small molecule therapies and more targeted biologics, are also on the horizon. Combining therapies may even become a strategy to improve results while minimizing side effects. In short, biologics have transformed the way we manage IBD, offering better disease control and improved quality of life. But research and innovation remain key to helping more people achieve lasting remission with fewer complications.

Brain tumors are critical neurological disorders, and early detection is essential for effective treatment. Traditional diagnostic methods, which rely on manual interpretation of medical images, are time-consuming, error-prone, and dependent on clinician expertise. With advancements in artificial intelligence (AI) and deep learning (DL), there has been significant progress in automating the detection and classification of brain tumors from medical images. However, a significant challenge remains: the limited availability of large, annotated datasets. Annotated data is expensive, scarce, and often subject to privacy concerns, making it difficult to fully leverage deep learning techniques. To address this issue, self-supervised learning (SSL) has emerged as a promising solution. SSL enables deep learning models to generate supervisory signals from unlabeled data, significantly reducing the need for manual annotation. This is particularly beneficial in medical imaging, where acquiring labeled data can be costly and time-consuming. SSL methods, such as contrastive learning, rotation prediction, and jigsaw puzzles, allow models to learn meaningful feature representations from unlabeled data, which can then be fine-tuned for tasks like tumor classification. Techniques like contrastive learning (e.g., SimCLR, MoCo, and BYOL), generative models (e.g., autoencoders and GANs), and clustering-based approaches (e.g., DeepCluster and SwAV) have shown success in learning from unlabeled medical images. In addition, SSL facilitates the integration of multiple imaging modalities, such as MRI, CT, and PET scans. By combining these modalities, SSL models can leverage complementary information, leading to enhanced tumor classification accuracy and robustness. Federated learning (FL) combined with SSL allows for collaborative model training across multiple institutions without sharing sensitive patient data, thus ensuring privacy. Despite the significant advancements in SSL for brain tumor classification, challenges remain. These include the need for small labeled datasets for fine-tuning, domain shifts across imaging modalities, interpretability issues, and the computational complexity of training deep SSL models. In conclusion, SSL has the potential to revolutionize brain tumor classification by reducing the reliance on large annotated datasets. Continued research into SSL techniques can lead to more accurate and efficient diagnostic tools, improving patient outcomes through earlier and more precise tumor detection.